Results 221 to 230 of about 229,435 (354)

Estrogen replacement therapy in patients with endometrial cancer: a survey of prescription intention of Belgian gynecologists [PDF]

, 1999
Serge Rozenberg, Jonathan B Vasquez
openalex   +1 more source

Mass spectrometry imaging of N‐linked glycans: Fundamentals and recent advances

Mass Spectrometry Reviews, EarlyView.
Abstract With implications in several medical conditions, N‐linked glycosylation is one of the most important posttranslation modifications present in all living organisms. Due to their nontemplate synthesis, glycan structures are extraordinarily complex and require multiple analytical techniques for complete structural elucidation.
Tana V. Palomino, David C. Muddiman
wiley   +1 more source

Endocrine therapy for endometrial cancer: traditional approaches and novel targets. [PDF]

Front Oncol
Guan X, Tang R, Yang J.
europepmc   +1 more source

The clinical usefulness of the endometrial cytology using Masubuchi's aspiration tubes in ovarian and fallopian tube cancer.

, 1994
Nobuhiro Takeshima, H Teshima, Atsuko MINAMP, Katsuyoshi Katase, Satoshi Umezawa, Yoshio Shimizu, I Fujimoto, Kazuhiro Yamauchi, Katsuhiko Hasumi, Masahumi TSUZUKU   +9 more
openalex   +2 more sources

RESPONSE: Re: Effects of the Antiestrogens Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer Growth [PDF]

, 1999
R. O'Regan
openalex   +1 more source

Identification of PPFIA3 as a Potential Prognostic and Immune Biomarker Through Pan‐Cancer Analysis

Organ Medicine, EarlyView.
This study reveals a significant increase in the expression of PPFIA3 across various cancers, which is associated with poor prognosis. Notably, in patients receiving anti‐PD‐L1 treatment, high PPFIA3 expression is closely linked to improved survival rates and favorable prognosis, suggesting its potential as a predictive factor for immune checkpoint ...
Xianghong Wang, Rong Lin, Chuanchuan Sun, Niujian Wu, Hongyun Lu   +4 more
wiley   +1 more source

Efficacy and mechanisms of Angelica sinensis in treating endometrial cancer: an integrated study. [PDF]

Discov Oncol
Li Z, Jia C, Zhou Y, Wang Q.
europepmc   +1 more source

Clinical Profile and Prognostic Factor of Endometrial Cancer [PDF]

, 1997
Su Yeon Kim, Sang Young Ryu, Jae‐Weon Kim, Noh Hyun Park, Yong Sang Song, Soon Beom Kang, Hyo Pyo Lee   +6 more
openalex   +1 more source

Activated immune infiltrates expand opportunities for targeted therapy in p53‐abnormal endometrial carcinoma

The Journal of Pathology, EarlyView.
Abstract Tumor protein p53 mutated/abnormal (p53abn) endometrial carcinomas account for over 50% of deaths but comprise only 15% of all endometrial carcinomas. Most patients show limited response to standard‐of‐care chemotherapy with or without radiotherapy, and only a minority of cases are amenable to targeted therapies like poly‐ADP ribose polymerase
Spencer D Martin, Shelby Thornton, Christine Chow, Katy Milne, Juliana Sobral de Barros, Kayleigh A Morris, Samuel Leung, Amy Jamieson, Brad H Nelson, Dawn R Cochrane, David G Huntsman, C Blake Gilks, Lien Hoang, Jessica N McAlpine, Allen W Zhang   +14 more
wiley   +1 more source

Abdominal fat distribution in endometrial cancer: from diagnosis to follow-up. [PDF]

BMC Cancer
Fasmer KE, Sæterstøl J, Ljunggren MBS, Brun AMK, Pijnenborg JMA, Woie K, Krakstad C, Haldorsen IS.   +7 more
europepmc   +1 more source